Magnetic Actuator
One Device.
Long-Term Stability. Built-In Sterility.
A device that extends drug stability, simplifies logistics, cuts costs, and enhances patient compliance and safety.
Rod-less Piston
Sealed Cartridge
Zero Leachables
Zero Air Bubbles
Multi-Format Compatible
Prolonged Storage
Built to replace the syringe, not improve it.
Relying on 70-year-old syringe technology costs the global healthcare industry over $35 billion annually. These outdated systems drive up costs through high drug wastage and expensive cold-chain logistics, while posing serious sterility and stability risks that make them ill-equipped to handle modern biologics.
Feature
Conventional Syringe
MIST System
Actuation
Plunger, manual push, direct contact.
Plunger-less, magnetically actuated
.
Sterility
Silicone oil lubricant — contamination and protein aggregation risk.
Zero silicone oil, zero contact — no leachables.
Dosing Accuracy
Air bubbles require overfill to compensate
Zero air bubbles, zero overfill
Cold Chain
Required for most biologics
Reduced or eliminated — vacuum/inert-gas sealed
Formulation Range
Liquids only; struggles with viscous or gas-based drugs
Liquids, viscous formulations, semi-solids, and gases
Cost Impact
Baseline
30–60% lower cold-chain cost, 10–18% lower drug waste
Actuation
Conventional Syringe
Plunger, manual push, direct contact.
MIST System
Plunger-less, magnetically actuated.
Sterility
Conventional Syringe
Silicone oil lubricant — contamination and protein aggregation risk.
MIST System
Zero silicone oil, zero contact — no leachables.
Dosing Accuracy
Conventional Syringe
Air bubbles require overfill to compensate
MIST System
Zero air bubbles, zero overfill
Cold Chain
Conventional Syringe
Required for most biologics
MIST System
Reduced or eliminated — vacuum/inert-gas sealed
Formulation Range
Conventional Syringe
Liquids only; struggles with viscous or gas-based drugs
MIST System
Liquids, viscous formulations, semi-solids, and gases
Cost Impact
Conventional Syringe
Baseline
MIST System
30–60% lower cold-chain cost, 10–18% lower drug waste
Our Team of Experts
Founded in 2026, Avicenna Therapeutic Tech, Inc., a DE C-corp. set out to solve a problem the industry had accepted: how to keep injectable medication stable and sterile without compromise.
Our team draws on decades of experience across medical devices, pharma, biotech, and manufacturing to bring MIST from concept to reality.
Learn More
Ready to Rethink Drug Delivery?
Whether you're a pharma partner, investor, or just curious about the technology, we'd love to talk.
